Journal
ISCIENCE
Volume 26, Issue 9, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2023.107730
Keywords
-
Categories
Ask authors/readers for more resources
This study found that selective inhibition of urate transporter-1 (URAT1) can improve cardiac fibrosis, inflammatory responses, and cardiac dysfunction induced by high-fat diet. URAT1 is also expressed in cardiomyocytes. Additionally, palmitic acid significantly increases URAT1 expression and induces apoptosis, oxidative stress, and inflammatory responses in cardiomyocytes, which can be attenuated by URAT1 selective inhibitor dotinurad.
We recently reported that the selective inhibition of urate transporter-1 (URAT1), which is primarily expressed in the kidneys, ameliorates insulin resistance by attenuating hepatic steatosis and improving brown adipose tissue function in diet-induced obesity. In this study, we evaluated the effects of dotinurad, a URAT1- selective inhibitor, on the hearts of high-fat diet (HFD)-fed obese mice for 16-20 weeks and on neonatal rat cardiomyocytes (NRCMs) exposed to palmitic acid. Outside the kidneys, URAT1 was also expressed in cardiomyocytes and indeed worked as a uric acid transporter. Dotinurad substantially attenuated HFD-induced cardiac fibrosis, inflammatory responses, and cardiac dysfunction. Intriguingly, among various factors related to the pathophysiology of diet-induced obesity, palmitic acid significantly increased URAT1 expression in NRCMs and subsequently induced apoptosis, oxidative stress, and inflammatory responses via MAPK pathway, all of which were reduced by dotinurad. These results indicate that URAT1 is a potential therapeutic target for metabolic heart disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available